From Chronic Inflammation to Cancer

June 4 – 5, 2010
Hotel Voronez
Brno, Czech Republic

Program
12 credit hours (CME) have been awarded for the Falk Symposium 173 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG).
Preface

It is with great pleasure that we invite you to this international symposium devoted to exploration of the connection between chronic inflammation and various malignancies of the gastrointestinal tract. We will proceed from the basic research that allows more and better understanding of the molecular mechanisms involved in the development and progression of GI malignancy to clinical management, which has seen significant advances in recent years.

Specifically, we will look at hepatobiliary cancer, taking hepatocellular and cholangiocellular carcinoma as clinical and basic-science models of the connection between inflammation and cancer. We will take a similar approach with chronic inflammation and cancer of the esophagus, stomach, bowel and pancreas, with special emphasis on advances in diagnosis and therapy.

Thanks to the generous support of the Falk Foundation, we have again been able to recruit a top-rate international faculty to provide up-to-the-minute inputs into this important exchange of experience and information.

The historical city of Brno will be a very appropriate setting for a meeting that places heavy emphasis on basic and molecular science and research. It was here at the Abbey of St. Thomas that Gregor Mendel, Augustinian priest and later abbot, scientist and teacher, working with pea plants and four o’clock flowers, laid the foundation for modern genetics. That foundation was long neglected and silted over, and it was only at the turn of the 20th century that his work came into its own as the basis for modern genetics, and with time and by extension, for the molecular genetics that today are the source of so much hue and cry.

Petr Díte, Brno, Czech Republic
Günter J. Krejs, Graz, Austria
Peter Malfertheiner, Magdeburg, Germany
Zsolt Tulassay, Budapest, Hungary
From Chronic Inflammation to Cancer

Hotel Voronez
Brno, Czech Republic

Registration:
Thursday, June 3, 2010
16.00 - 21.00 h
at the congress office

Information:
Prof. Dr. Petr Díte
Masaryk University Hospital
Department of Internal Medicine & Gastroenterology
Jihlavská 20
639 00 Brno
Czech Republic
Telephone: +420(0)5/32 23 35 00
Telefax: +420(0)5/32 23 32 54
E-mail: pdite@fnbrno.cz

Official Language:
English

Poster session:
For details see page 10

Scientific Organization:
P. Díte, Brno (Czech Republic)
G. J. Krejs, Graz (Austria)
P. Malfertheiner Magdeburg (Germany)
Z. Tulassay, Budapest (Hungary)

Congress Venue:
Hotel Voronez
Kriskovskeho 47
Brno
Czech Republic
Friday, June 4, 2010

8.15 Welcome  P. Díte, Brno

Session I
Chronic inflammation

Chairmen: P. Díte, Brno; F. Farinati, Padua

8.30 Inflammation and immunity in the tumor microenvironment  J. Emmrich, Rostock

9.00 Oxidative stress and iNOS induction in carcinogenesis  F. Farinati, Padua

9.30 Role of COX in pathogenesis and prevention in the development of GI tumors  N. Arber, Tel Aviv

10.00 Chronic inflammation and gene polymorphism  C. R. Boland, Dallas

10.30 Coffee break with poster session

Session II
Liver malignancies

Chairmen: L. Kuzela, Bratislava; F. Szalay, Budapest

11.00 Chronic hepatitis – Risk factor for hepatic carcinoma  J. Lata, Brno

11.30 The diagnostic and therapeutic approach for primary solid liver tumors in adults  M. Pech, Magdeburg

12.00 Biliary tract cancers – Pathogenesis and risk factors  G. Ramadori, Goettingen

12.30 Endoscopic therapy of biliary tract malignancies  T. Marek, Katowice

13.00 Lunch break with poster session
Friday, June 4, 2010

Session III
Gastric cancer

Chairmen: G. J. Krejs, Graz; Z. Tulassay, Budapest

14.00 Epidemiology

14.30 Molecular pathogenesis of H. pylori infection – The role of bacterial virulence factors

15.00 H. pylori infection and gastric carcinogenesis and the potential of prevention

15.30 Multimodal therapy of gastric cancer

16.00 Coffee break with poster session

Session IV
Colorectal cancer

Chairmen: J. Regula, Warsaw; S. Suchanek, Prague

16.30 IBD as a risk factor for colorectal cancer

17.00 The use of molecular markers in diagnosis of colorectal cancer screening

17.30 Advanced colonoscopic imaging

18.00 Rectal cancer highlights from the Czech National Cancer Registry

18.30 End of afternoon session
Saturday, June 5, 2010

Session V
Esophageal cancer

Chairmen: H. Hammer, Graz; P. Malfertheiner, Magdeburg

9.00 Etiology and risk factors for esophageal carcinoma
     L. Lundell, Stockholm

9.30 Esophageal carcinogenesis
     K. E. L. McColl, Glasgow

10.00 New diagnostic endoscopic approaches of esophageal cancer
     R. Kiesslich, Mainz

10.30 Multimodal treatment of esophageal cancer
     J. Zacherl, Vienna

11.00 Coffee break with poster session

Session VI
State-of-the-art-lecture
Dr. Herbert Falk memorial lecture

Chairmen: P. Díte, Brno

11.30 Advances in screening for gut malignancies
     M. Classen, Munich

12.10 Lunch break with poster session
Saturday, June 5, 2010

13.10 Presentation of Poster Prizes  
P. Díte, Brno

Session VII
Pancreatic cancer

Chairmen: M. J. Bruno, Rotterdam; H. Friess, Munich

13.15 Pancreatic cancer – Epidemiology  
P. Maisonneuve, Milan

13.45 Chronic pancreatitis and pancreatic cancer  
S. S. Vege, Rochester

14.15 Is early diagnosis of pancreatic cancer fiction?  
M. J. Bruno, Rotterdam

14.45 Coffee break with poster session

15.15 What’s new in therapy of pancreatic cancer  
J. Moessner, Leipzig

15.45 Adjuvant therapy of pancreatic cancer  
P. Ghaneh, Liverpool

16.15 End of meeting
Poster Session

Posters will be exhibited on June 4 - 5, 2010 at the Hotel Voronez.
The authors will be in attendance during coffee and lunch breaks on both days.

Basic Science

1. 5-Aminosalicylic acid induced multisystem disorders in the course of Crohn’s disease
   E. Akbal, S. Köklü, E. Kocak, B. Cakal, F. Kilic (Ankara, TR)

2. HER-2/neu - Protein marker of poor prognosis in gastric cancer
   J. Ananiev, M.V. Gulubova, I.M. Manolova (Stara Zagora, BG)

   A.F. Barbu, S.T. Barbu, I. Lupu (Cluj-Napoca, RO)

4. Progression of pancreatic intraepithelial neoplasia to invasive adenocarcinoma
   in chronic pancreatitis patients
   S.T. Barbu, I. Domsa, A. Zolog, M. Cazacu (Cluj-Napoca, RO)

5. Gastric serrated adenoma polyp treated with endoscopic band ligation
   O. Basar, S. Köklü, E. Akbal, M. Ibis (Ankara, TR)

6. Pseudotumoral proctitis associated with the long-term use of diclofenac
   suppositories
   A. Berecz, D. Berecz (Odorheiu Secuiesc, RO)

7. IL-23 is a key pathogenic inducer of chronic intestinal inflammation
   U. Billmeier, M.F. Neurath, S. Wirtz (Erlangen, D)

8. Screening of patients with Crohn’s disease (CD) and ulcerative colitis (UC) for
   malnutrition is a MUST
   I. Chermesh, T. Mashiach, A. Karban, R. Eliakim (Haifa, IL)

9. Chronic pancreatitis and pancreatic cancer - Mortality risk factors
   O.P. Ciof, A. Tudora, I. Sporea (Timisoara, RO)

10. The lymphoid aggregates and the bile duct lesions in chronic hepatitis C patients
    D. Damian, M. Grigorescu, T. Zaharie, M.D. Grigorescu (Cluj-Napoca, RO)

11. Hepatic steatosis and chronic hepatitis C
    D. Damian, M. Grigorescu, T. Zaharie, T. Mocanu (Cluj-Napoca, RO)

12. The necroinflammatory activity and the hepatic fibrosis in patients with
    chronic hepatitis C
    D. Damian, M. Grigorescu, M.D. Grigorescu, T. Zaharie, T. Mocanu (Cluj-Napoca, RO)
13. Palliative treatment of hepatocellular carcinoma in Romania  
D.N. Dascalu (Sibiu, RO)

14. Trends of primary and subsequent cancers of gastrointestinum in the Czech population  
P. Díte, E. Geryk, L. Pecen (Brno, CZ)

15. Overexpression of a splice variant of Smurf2 in T-cells upregulates the TGF-beta signalling pathway and protects mice from experimental colon cancer  
H. Dornhoff, C. Becker, M.F. Neurath (Erlangen, D)

16. The importance of anti-dsDNA antibody in autoimmune hepatitis/primary biliary cirrhosis overlap syndrome  
C. Efe, T. Purnak, E. Ozaslan (Bitlis, Ankara, TR)

17. An ultrastructural study of hepatic stellate cells in relation to carcinogenesis in patients with hepatitis C virus infection  
N. Elkhafif, S. Mansy, H. Yehia, A. Abd el Fatah, I. Mostafa, N.M. El Assaly (Giza, ET)

18. Prediction of clinical outcome in chronic hepatitis due to HCV genotype 4 after combination therapy with pegylated interferon -2a and ribavirin  
N. Elkhafif, N.M. El Assaly, N. El Ashri, O. El Bendary, S.M. Shendy, M.A. Saber, E. El Dabaa (Giza, ET)

19. IBD: Molecular markers in diagnosis of colorectal cancer  
O.V. Fedorova, E. Fedulova, O. Tutina, G.V. Medyantseva (Nizhny Novgorod, R)

20. Morphological predictors of cancer degeneration in ulcerative colitis  
E. Fedulova, P. Potehin, O. Fedorova, O. Tutina (Nizhny Novgorod, R)

21. Ultrastructural and COX-2 immunohistochemical assessment of longstanding ulcerative colitis related dysplasia  
O. Fratila, C. Craciun, D. Dumitrascu, R. Mihaila, M. Puscasiu (Oradea, Cluj-Napoca, Sibiu, RO)

22. Contribution of hepatitis C virus infection to development of hepatocellular carcinoma  
A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut (Craiova, RO)

23. Analysis of development of gastric cancer in patients with Helicobacter pylori eradicated comparative with never infected patients  
A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut (Craiova, RO)

24. Colorectal polyps carcinogenesis - Possible risk factors  
A. Goldis, D. Lazar, R. Goldis, A. Muresan, S. Taban, V. Lungu, V. Danila (Timisoara, RO)
25. Epidemiological trends of inflammatory bowel diseases (IBD) in the west part of Romania
   A. Goldis, D. Lazar, I. Ratiu, M. Ionita, D. Koukoulas, A. Muresan (Timisoara, RO)

26. Prognostic significance of the clinicopathological factors in gastric cancer
   R. Goldis, A. Goldis, D. Lazar, S. Taban, A. Muresan, A. Dema, M. Cornianu,
   I. Ratiu, E. Lazar (Timisoara, RO)

27. Development of colonic cancer - Possible risk factors
   R. Goldis, A. Goldis, D. Lazar, A. Muresan, V. Lungu (Timisoara, RO)

28. Transforming growth factor-beta 1 promoter polymorphism, colorectal cancer susceptibility and prognosis
   M.V. Gulubova, I.M. Manolova, L. Miteva (Stara Zagora, BG)

29. Helicobacter pylori infection and expressions of EGF, EGFR and c-erB-2 proteins in gastric carcinoma
   K. Guzinska-Ustymowicz, A. Pryczynicz, M. Sokolowski, J. Czyzewska, V. Dymicka-Piekarska, D. Cepowicz, B. Kedra, A. Kemona (Bialystok, PL)

30. COX-2 and p53 correlations in chronic inflammation leading to dysplastic changes in longstanding ulcerative colitis
   T. Ilias, O. Fratila, D. Puscasu, A. Maghiar, T.T. Maghiar (Oradea, RO)

31. From chronic mixed infection to cancer: Case Report
   M. Kanashvili, M. Makhviladze, N. Rukhadze, T. Kuchuloria, B. Kanashvili,
   S. Gogichaishvili, N. Okrostvsvaridze (Tbilisi, GEO)

32. Fluorescence in situ hybridization biomarkers of gastric cancer risk in intestinalized Helicobacter pylori pangastritis
   B.W. Kim, M.P. Bronner (Seoul, ROK; Cleveland, USA)

33. Implication of Notch signaling and CDX-2 expression in Barrett’s carcinogenesis
   P. Konturek, G. Burnat (Saalfeld, Erlangen, D)

34. Laparoscopic gastric GIST resection
   (Debrecen, H)

35. Prognostic significance of the cyclooxygenase-2 (COX-2) immunohistochemical expression in gastric cancer
   D. Lazar, S. Taban, E. Lazar, A. Dema, M. Cornianu, I. Ratiu, A. Goldis, I. Sporea
   (Timisoara, RO)

36. Hepatic carcinoma as outcome of natural course of liver cirrhosis
   B.N. Levitan, E. Popov, G. Levitan (Astrakhan, R)
37. Clinical utility of red cell distribution width (RDW) in active inflammatory bowel disease
   V. Licul, B. Mijandrusic Sincic, I. Mikolasevic, S. Milic, D. Stimac (Rijeka, HR)

38. Role of CD24 polymorphisms in the susceptibility to inflammatory bowel disease
   V. Lisiansky, M. Moshkowitz, I. Naumov, D. Kazanov, L. Galazan, S. Kraus, M. Leshno, N. Arber (Tel Aviv, IL)

39. Increased tissue levels of transforming growth factor-beta 1 in patients with advanced colorectal cancer
   I.M. Manolova, M.V. Gulubova, J. Ananiev (Stara Zagora, BG)

40. Adenosine deaminase activity and its isoenzymes in patients with Crohn’s disease
   I. Maor, T. Rainis, A. Lanir, A. Lavy (Haifa, IL)

41. Gene expression and genetic polymorphisms in TLR4 and COX-2 genes in inflammatory bowel disease and colorectal adenomas
   A. Ocepek, P. Skok, U. Potocnik (Maribor, SLO)

42. Acute seronegative autoimmune hepatitis
   E. Ozaslan, U. Samsar, E. Erden (Ankara, TR)

43. Intestinal lymphoma in a patient with Crohn’s disease - Is there any interdependence?
   O. Petrascu, M. Deac, R.G. Mihaila, A.B. Boicean (Sibiu, RO)

44. Diabetes mellitus and pancreatic cancer: A case-control study in Albania
   S. Prifti, B. Kraja, M. Sina, N. Dhigoi, I. Akshia (Tirana, AL)

45. Fas/FasL expression in IBD and colorectal cancer
   A. Pryczynicz, K. Guzinska-Ustymowicz, M. Sokolowski, J. Czyzewska, V. Dymicka-Piekarska, D. Cepowicz, B. Kedra, A. Kemona (Bialystok, PL)

46. Myeloperoxidase (MPO-463) gene polymorphism in the pathogenesis of gastric and duodenal ulcers
   A. Prystupa, K. Król, G. Dzida, J. Mosiewicz (Lublin, PL)

47. PCNA and VEGFR expression in colon cancer prognosis
   C. Searpe, V. Sbarcea, L. Mogoanta, M. Tenovici, M. Searpe (Craiova, RO)

48. The implication of Helicobacter pylori infection, anti-parietal cell antibodies and cytokines in the degree of atrophic gastritis
   C.A. Silosi, I. Silosi, V. Biciusca, O. Drackoulogona (Craiova, RO; Patra, GR)

49. The total gastrectomy in gastric cancer
   C.A. Silosi, I. Silosi (Craiova, RO)
50. Considerations in the immunohistochemical diagnosis of malignant soft tissue tumors of mesenchymal origin
   I. Silosi, C.A. Silosi, V. Biciusca (Craiova, RO)

51. Colorectal malignancies and chronic inflammation in UC: Is JC virus involved?
   D. Stoyanova, I. Tsekov, D. Dardanov, K. Katzarov, G. Kirov, Z. Kalvatchev (Sofia, BG)

52. Laboratory testing of sera after precutan drainage of the sterile peripancreatic fluid in patients with acute pancreatitis
   Z. Szentkereszty, R. Kotán, J. Pósán, L. Sasi Szabó, P. Sápy, S. Sipka, L. Damjanovich (Debrecen, H)

53. An unusual metastasis from a primary colonic adenocarcinoma
   S. Taban, A. Dema, E. Lazar, M. Cornianu, D. Lazar, E. Cev (Timisoara, RO)

54. Incidence of constipation, ulcerative colitis and colorectal cancer in Dushanbe
   M.S. Tabarov, N.A. Nuriloeva, Z.M. Toshtemirova, K. Shemerovsky (Dushanbe, TAD; St. Petersburg, R)

55. Long-term follow-up and risk for colorectal cancer in patients with ulcerative colitis from Moldova
   S. Turcan, V. Dumbrava, R. Tanase, S. Barca (Chisinau, MOL)

56. Dysplasia and the risk for colorectal cancer in ulcerative colitis
   V. Vacariu, C. Banciu, I. Romosan, N. Tudose, E. Potencz (Timisoara, RO)

57. Gastric cancer in elderly patients
   V. Vacariu, C. Banciu, I. Romosan, L. Susan, I.A. Szucsik (Timisoara, RO)

58. Analyzing the role of mucosal mast cells inducing colitis-associated colorectal cancer (CRC)
   B. Weigmann, M. Stassen, C. Taube, M.F. Neurath (Erlangen, Mainz, D)

59. Both MGMT- and AAG-dependent DNA repair mechanisms protect against inflammation-dependent colon carcinogenesis
   S. Wirtz, G. Nagel, L. Samson, B. Kaina, M.F. Neurath (Erlangen, Mainz, D; Cambridge, USA)

60. Epithelial STAT3 links chronic intestinal inflammation to colon cancer
List of Speakers, Moderators and Scientific Organizers

Prof. Dr. Nadir Arber
Tel Aviv Medical Center
Ichilov Hospital
Department of Gastroenterology
6, Weizman Street
64239 Tel Aviv
Israel
nadir@tasmc.health.gov.il

C. Richard Boland, M.D.
Professor of Medicine
University of Texas
Baylor Medical Center
Division of Gastroenterology
3500 Gaston Ave.
Dallas TX 75246-2045
USA
rickbo@baylorhealth.edu

Prof. Dr. Marco J. Bruno
Erasmus Medical Center
Department of Gastroenterology
Dr. Molewaterplein 40
3015 GD Rotterdam
Netherlands
m.bruno@erasusmc.nl

Prof. Dr. Jörg Emmrich
Gastroenterologie
Klinikum der Universität Rostock
Ernst-Heydemann-Str. 6
18057 Rostock
Germany
joerg.emmrich@med.uni-rostock.de

Prof. Dr. Fabio Farinati
Università di Padova
Clinica Medica 2
Department of Surgical and Gastroenterological Sciences
Via Giustinian 2
35128 Padua
Italy
fabio.farinati@unipd.it

Prof. Dr. Helmut Friess
Chirurgie
Klinikum rechts der Isar der Technischen Universität
Ismaninger Str. 22
81675 Munich
Germany
helmut.friess@chir.med.tu-muenchen.de

Prof. Dr. Petr Dite
Masaryk University Hospital
Department of Internal Medicine & Gastroenterology
Jihlavská 20
639 00 Brno
Czech Republic
pdite@fnbrno.cz

Prof. Dr. Dr. h. c. mult.
Meinhard Classen
Unsöldstr. 5
80538 Munich
Germany
meinhard.classen@lrz.tum.de

Dr. Paula Ghaneh
Royal Liverpool University Hospital
Division of Surgery & Oncology
Daulby Street
Liverpool L69 3GA
Great Britain
p.ghaneh@liverpool.ac.uk

Dr. Heinz Hammer
Medizinische Universität Graz
Auenbruggerplatz 15
8036 Graz
Austria
heinz.hammer@medunigraz.at
Congress Office

During the Falk Symposium 173

Hotel Voronez Krizkovskeho 47 Brno
Telephone: +420(5) 43 14 11 54 Telefax: +420(5) 43 14 11 54
Czech Republic

Opening Hours:
Thursday, June 3, 2010 16.00 – 21.00 h
Friday, June 4, 2010 7.30 – 18.30 h
Saturday, June 5, 2010 8.30 – 16.15 h

Congress Fees

Scientific program of the Falk Symposium 173

€ 200,-

Students and residents

€ 100,-

* * * OR * * *

Day ticket

€ 120,-

Students and residents

€ 60,-

The congress fees include:
- Welcome Evening on June 3, 2010
- Refreshments during coffee breaks
- Lunch on June 4 and 5, 2010
- A copy of the abstract volume

Admission to Scientific Events

For admission to scientific events your name badge should be clearly visible.
**Congress Report**

The official congress report of the Falk Symposium 173 “From Chronic Inflammation to Cancer” will be published in English in the first half of 2011 by Karger Publishers, Basel. Orders for this book at a reduced subscription price of € 35,- can be placed at the Congress Office during the congress in Brno.

**Congress Short Report**

The congress short report of the Falk Symposium 173 “From Chronic Inflammation to Cancer” will be published by the Falk Foundation e.V. with number FSK 173 in the second half on 2010.

Orders for this short report, free of charge, can be placed with the Falk Foundation e.V.

**Airport**

International Airports Vienna and Prague